## **What is the HCPCS code J2778 for?**
The HCPCS code J2778 is meant to designate an injection of a medicine called ranibizumab, specifically a 0.1 mg dose. Ranibizuman is a vascular endothelial growth factor (VEGF-A) inhibitor, a type of pharmacologic agent that comes in a single-use vial, and it requires intravitreal administration. Its purpose is to serve as an eye injection meant to combat certain eye conditions that ultimately lead to the loss of vision. The branded name for this injection is Lucentis Injection.
Such conditions include the following:
- Proliferative diabetic retinopathy
- Age-related macular degeneration (AMD)
- Retinal vein occlusion
- Rhegmatogenous retinal detachment
- Choroidal neovascularization
- Diabetic macular edema
What this medicine does is reduce vision loss and improve a person's vision by shrinking any swelling caused by the aforementioned conditions, and to prevent abnormal blood vessels from forming in the affected eye(s).
## **Documentation requirements for J2778**
As with any procedure, especially involving injecting drugs into patients, it's important to document the following before you file for a claim that includes this intravitreal injection:
- The full name of the personnel who administered the injection + their credentials
- The name and address of the facility where the injection was administered
- The full name of the patient
- The patient's consent to the injection
- The date and time of the drug administration by injection, plus the laterality
- Patient records showing they have been diagnosed with an eye condition that impacts their vision
- Imaging tests results of the affected eye(s) showing swelling, abnormal blood vessel formations, and other problems contributing to the vision loss
- The exact dosage
## **Billing requirements for J2778**
Besides the documentation requirements above, please note the following billing requirements for this HCPCS code:
- They must reflect the dosage given over the course of the treatment.
- Use either of these two modifiers: JW if there's unused medication in a vial (wastage), or JZ if there's no unused medication.
- Use of laterality-related modifiers is important, too. Bilateral services must be reported on separate lines using an RT and LT modifier. You're not allowed to use bilateral modifier 50.
Documentation and billing must follow local coverage determinations, CMS, Medicare or Medicaid services guidelines to avoid claim rejections.
## **Other similar codes**
- J2786 - Injection, reslizumab, 1 mg
- J2785 - Injection, regadenoson, 0.1 mg
- J2783 - Injection, rasburicase, 0.5 mg
- J9223 - Injection, lurbinectedin, 0.1 mg
- J3396 - Injection, verteporfin, 0.1 mg
Frequently asked questions
